The FTD-positive myeloid cells in the bone marrow of patients who received TFTD medication may escape cell death, but stop proliferating, possibly because of p53-dependent sustained arrest at G2 phase21, differentiate into lymphoid cells and PBMCs and circulate in the bloodstream in a quiescent state. Here, TP53 is linked to frontotemporal dementia.